Format

Send to

Choose Destination
Int J Gynaecol Obstet. 2019 Apr;145(1):129-135. doi: 10.1002/ijgo.12749. Epub 2019 Jan 17.

Revised FIGO staging for carcinoma of the cervix uteri.

Author information

1
Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
2
Stanford Women's Cancer Center, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
3
Division Obstetrics and Gynecology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
4
Department of Obstetrics and Gynaecology, Groote Schuur Hospital and SAMRC Gynaecology Cancer Research Centre, University of Cape Town, Cape Town, South Africa.
5
University of Turku and Department of Obstetrics and Gynecology, Turku University Hospital, Turku, Finland.
6
Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
7
University of Birmingham and St. Peters College, Oxford, UK.
8
National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
9
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
10
Autonomous University of Barcelona, Barcelona, Spain.
11
International Agency for Research on Cancer (WHO-IARC), Lyon, France.
12
RTI International India, New Delhi, India.

Abstract

OBJECTIVE:

To revise FIGO staging of carcinoma of the cervix uteri, allowing incorporation of imaging and/or pathological findings, and clinical assessment of tumor size and disease extent.

METHODS:

Review of literature and consensus view of the FIGO Gynecologic Oncology Committee and related societies and organizations.

RESULTS:

In stage I, revision of the definition of microinvasion and lesion size as follows. Stage IA: lateral extension measurement is removed; stage IB has three subgroups-stage IB1: invasive carcinomas ≥5 mm and <2 cm in greatest diameter; stage IB2: tumors 2-4 cm; stage IB3: tumors ≥4 cm. Imaging or pathology findings may be used to assess retroperitoneal lymph nodes; if metastatic, the case is assigned stage IIIC; if only pelvic lymph nodes, the case is assigned stage IIIC1; if para-aortic nodes are involved, the case is assigned stage IIIC2. Notations 'r' and 'p' will indicate the method used to derive the stage-i.e., imaging or pathology, respectively-and should be recorded. Routine investigations and other methods (e.g., examination under anesthesia, cystoscopy, proctoscopy, etc.) are not mandatory and are to be recommended based on clinical findings and standard of care.

CONCLUSION:

The revised cervical cancer staging is applicable to all resource levels. Data collection and publication will inform future revisions.

KEYWORDS:

FIGO ; Cancer; Carcinoma; Cervix; Imaging; Revised; Staging

PMID:
30656645
DOI:
10.1002/ijgo.12749
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center